Business:
Gene Therapy, Devices, Biologics, Small Molecules all for DMD
Drug notes:
ABV-202 Clin0 Friedreich's ataxia; AVB-401 Clin0 dilated cardiomyopathy; undisclosed Clin0 cardiac condition
About:
Solid Biosciences is advancing genetic medicines to treat patients with neuromuscular and cardiac diseases. To create effective therapies, Solid has built a state-of-the-art process development and characterization lab to establish their transient transfection-based gene therapies. Solid’s pipeline includes SGT-003, a treatment for Duchenne muscular dystrophy and AVB-401, a treatment for BAG3-mediated dilated cardiomyopathy. As the programs progress, Solid will continue to refine their manufacturing process so that they can meet their goal of ensuring that no patient goes without therapy.
Associate Director, Upstream Boston, MA|15 days ago
Senior Associate Scientist II-Protein Scientist Boston, MA|17 days ago
Director, Regulatory Strategy Boston, MA|28 days ago
Director, Data Management Boston, MA|30 days ago
Program Lead, PPM Boston, MA|39 days ago
Associate Medical Director, Clinical Development Boston, MA|61 days ago
Scientist II, Upstream Boston, MA|79 days ago
Director/Sr Director, Supply Chain United States|Not provided
Director of Predictive Sciences United States|Not provided